Published: 15 April 2020
Author(s): Florina Frîngu, Dumitru Zdrenghea, Raluca Tomoaia, Alexandra Dădârlat-Pop, Dana Pop
Issue: August 2020
Section: Letter to the Editor

The presence of diabetes mellitus (DM) in patients with cardiovascular disease is associated with a greater number of major adverse events [1]. One of the most severe consequences is represented by heart failure (HF). A major role in the correct and swift diagnosis of HF in diabetic individuals could be attributed to specific biomarkers mentioned by the current clinical practice guidelines: NT-proBNP, Galectine-3 and sST2 [2]. Galectine-3 (Gal-3) was proved to have an important role in mediating myocardial fibrosis, inflammation and pathological cardiac remodeling, conferring it a high predictive value for future cardiovascular adverse events, like readmission for HF and overall mortality.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.